Systemic lupus erythematosus

Questions discussed in this category

Have you seen drug induced SCLE from IL-17 inhibitors?

And if so, what is your approach to the diagnosis?

Do you continue belimumab throughout pregnancy?

How will you utilize newly FDA approved anifrolumab for SLE in your practice?

Would you consider utilizing a TNF-inhibitor in a patient with RA/SLE overlap who has already tried methotrexate, hydroxychloroquine, and abatacept?

Female patient in her 20's with RA/SLE has been on steroids and methotrexate, currently on HCQ and Orencia. Failing Orencia with active disease. Want ...

4 Answers available

How do you approach “clearing” a patient with SLE and ESRD for renal transplant?

A specific example would be a clinically quiescent but serologically active patient.

1 Answer available

How do you approach management of patients with lupus and transverse myelitis not responding to pulse dose steroids?

2 Answers available

What is your approach to using medications that can cause bone marrow suppression in SLE patients who have persistent leukopenia?

3 Answers available

Would you stop belimumab in a patient with SLE starting ravulizumab (C5 inhibitor) for myasthenia gravis due to concern for additive immunosuppression?

3 Answers available

Are there concerns with using sulfasalazine in SLE?

Extrapolating from reactions with other sulfa medications potentially causes flares.

1 Answer available

How do you monitor patients with cutaneous lupus for progression to SLE?

Do you do blood work? Or do you rely on review of systems?

1 Answer available

Is there practical utility from obtaining CSF autoantibodies in patients with suspected neuropsychiatric systemic lupus erythematosus?

1 Answer available

What is your approach to monitoring a patient with SLE who has persistent hypocomplementemia on hydroxychloroquine, but clinically has resolution of cutaneous symptoms and no other internal organ manifestations of disease?

(C3 just below normal, C4 undetectable)

2 Answers available

What is your workup for CSF studies when evaluating for possible CNS Lupus?

In addition, what formula do you use to calculate the IgG index?

2 Answers available

Would you use belimumab in a breastfeeding patient with SLE who has persistent joint pain, leukopenia and elevated dsDNA despite HCQ and azathioprine?

1 Answer available

What is your approach to pharmacologic treatment options in a patient with both SLE and Crohn's disease?

A female in her 50s with iatrogenic Cushing's Syndrome presenting for management of SLE with low disease activity (but not remission) in the setting o...

1 Answer available

How do you approach follow up of young patients with isolated +ANA, but no current clinical signs or symptoms of SLE?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Antibodies Before SLE.

6 Answers available

Would you escalate treatment for a clinically stable/asymptomatic lupus patient with persistent leukopenia/neutropenia, already on hydroxychloroquine?

6 Answers available

What would be your approach to a SLE patient who is triple APS positive, has no prior VTE/obstetric events, is stable on HCQ and low dose aspirin, and wants to become pregnant?

2 Answers available

When prescribing hydroxychloroquine, how do you explain the mechanism of action and how this translates into clinical benefit for the patient?

There are studies that show hydroxychloroquine inhibits autophagy (the orderly degradation and recycling of the contents of the cytoplasm for the cell...

3 Answers available

How would you approach a patient who has well controlled SLE on HCQ but develops cotton wool spots on routine ophthalmologic screening?

4 Answers available

What is your approach to assessing whether oral/nasal ulcerations are features of systemic lupus erythematosus versus from another etiology?

Classically, lupus mouth ulcers are large non-painful blisters at the roof of the mouth. What do you do with small scattered blisters, painful or not ...

1 Answer available

What is your approach to further work-up and management of neutropenia in patients with SLE/RA overlap?

For example, a patient with a bone marrow biopsy that shows normocellular bone marrow. Prior management with leflunomide and HCQ with neutropenia attr...

2 Answers available

Would you use TNF inhibitors in patients with features of SLE, but active peripheral and axial spondylarthritis?

Patient with sacroiliitis on imaging, failure of two NSAIDs.

2 Answers available

What is your approach to discordant dsDNA testing, such as positivity to dsDNA by crithidia but negativity to dsDNA by other modalities?

I get a lot of low false positive ds dna (sometimes high- 300) in quest and labcorp but their crithidia specific dsDNA labs when repeated are ne...

1 Answer available

Do you ever consider discontinuing hydroxychloroquine in patients with SLE in longstanding remission except in cases of overt toxicity?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Hydroxychloroquine Withdrawal.

2 Answers available

How would you interpret a positive dsDNA in a patient with a negative ANA performed via indirect immunofluorescence?

4 Answers available

Do you use anti-DFS70 Ab to help reduce the posttest probability of ANA-positive patients having a systemic autoimmune disease if other autoantibodies are negative?

ANA patients referred to rule out CTD is a work-intensive, costly referral type. If they are positive for Anti-Dense Fine Speckled Protein 70 kDa (DFS...

1 Answer available

What is your approach to checking IgG levels post vaccination to detect common variable immunodeficiency in patients with systemic lupus?

If a deficiency is present, do you consider IVIG to treat non-infectious symptoms such as skin rash, arthritis or hematological abnormalities?

1 Answer available

Is there a role for hydroxychloroquine for secondary prevention in patients with APS without SLE?

1 Answer available

How do you manage recurrent inflammatory pleural effusions in lupus pleuritis?

1 Answer available

Is there a role for measuring serum mycophenolate mofetil levels (or its active metabolite) in the management of lupus nephritis?

1 Answer available

How do you approach a negative ANA and positive dsDNA in patients who have arthralgia, hair loss or other UCTD features?

5 Answers available

Do you measure drug levels (particularly hydroxychloroquine or mycophenolate) in your lupus patients?

Several speakers at ACR 2021 commented on the important role of drug levels in the management of these patients and cautioned against adding medicatio...

1 Answer available

Are there any major differences in clinical manifestations or autoantibody profiles in children with SLE based on ethnicity?

2 Answers available

Would you consider using DOACs in a young patient with SLE and Libman-Sacks endocarditis, who is negative for APS?

2 Answers available

Do you routinely monitor the QTc when adding voclosporin to hydroxychloroquine in a patient with lupus nephritis?

1 Answer available

Would you consider use of belimumab in a patient with SLE with recurrent anterior uveitis who failed other treatment options?

Patient failed topical ocular therapies, methotrexate, azathioprine.

2 Answers available

What do you use for treatment induction in pure class V lupus nephritis with nephrotic-range proteinuria when MMF is contraindicated?

2 Answers available

In which clinical scenarios is relying on the urine protein-to-creatinine ratio as a measure of proteinuria unreliable, and interpretations should be made looking at urine protein and urine creatinine separately?

1 Answer available

What are some explanations for the persistent renal outcome disparity gaps affecting certain minority groups of patients with pediatric SLE despite improvement in overall renal outcomes?

What would you suggest to help address these disparities in our own practices?

2 Answers available

How can ethnic representation in clinical research studies in childhood and adult SLE be improved?

2 Answers available

What are the reasons for SLE specific labs to turn negative?

Patients frequently mention diagnosis of SLE years ago but recent Sm, dsDNA (crithidia) and complements can be normal. Can treatment with medications ...

5 Answers available

How do you gain access to quinacrine, and what has your recent experience been?

How long has it been back on the market? What is the typical cost for patients? Are certain compounding pharmacies regularly carrying it?

4 Answers available

How do you approach recurrent costochondritis in an SLE patient with nephritis who is otherwise controlled on MMF and HCQ but can't take NSAIDs?

2 Answers available

How would you approach the treatment of a patient who, during a hospitalization, was initially diagnosed with TTP and treated with PLEX with good response, but renal biopsy then resulted class IV LN along with changes of thrombotic microangiopathy?

4 Answers available

What is your treatment approach to persistent chillblains lesions in the absence of systemic lupus?

1 Answer available

What is your approach to the diagnosis and management of lupus cystitis?

2 Answers available

Are whole blood hydroxychloroquine blood levels helpful in patients taking chloroquine?

And if so, are the target levels similar?

2 Answers available

What is your approach to patients with SLE who develop rash after hydroxychloroquine initiation?

1 Answer available

Do you routinely check G6PD level prior to initiation of hydroxychloroquine?

6 Answers available

How would you treat a patient with active lupus nephritis (class 3/4) who requires PD-1 immunotherapy for refractory metastatic renal cell carcinoma?

2 Answers available

In patients with lupus nephritis on maintenance therapy, is there additional benefit in utilizing 2 grams vs 3 grams of mycophenolate mofetil (MMF) daily?

3 Answers available

What is your approach to severe discoid lupus refractory to conventional topical and systemic therapies?

(Refractory to mycophenolate, azathioprine, and methotrexate. UpToDate suggests thalidomide or IVIG with mixed efficacy, while there are some case rep...

4 Answers available

Is there a role for low dose aspirin in a patient with AVN in four large joints who has underlying well-controlled SLE and positive APLs but no history of clots?

1 Answer available

How do you approach the continued use of TNF inhibitors in a patient with inflammatory arthritis who develops a positive dsDNA without clinical evidence of drug-induced lupus?

2 Answers available

How would you approach initiating belimumab in a patient with serologic evidence of prior hepatitis B infection?

Such as patients with negative Hepatitis B surface antigen and negative viral load but with positive hepatitis b core antibody.

1 Answer available

What is your approach to ongoing assessment and medication tapering in well controlled discoid lupus without systemic features?

3 Answers available

How long would you consider the use of low-dose aspirin in a patient with SLE and high risk aPL profile (without a clinical event)?

1 Answer available

How do you approach the treatment of bullous cutaneous lupus?

When would you de-escalate therapy?

1 Answer available

What is your approach to management of ongoing scleritis in SLE despite mycophenolate?

1 Answer available

What is your approach to using NIH activity and chronicity indices from renal biopsy in tailoring immunosuppression to a patient with new lupus nephritis?

3 Answers available

Would you consider adding voclosporin to belimumab and MMF in the setting of active proteinuria, rather than switching agents?

3 Answers available

In your experience, is there an association between interstitial cystitis and systemic lupus erythematosus?

2 Answers available

Would you consider the use of rilonacept to treat refractory pericarditis in lupus?

4 Answers available

What workup and initial treatment should be considered for suspected autoimmune myelofibrosis?

1 Answer available

Would you consider PLEX for patients with DAH from SLE-associated capillaritis?

1 Answer available

What have you found effective for the chronic fatigue that is often seen in patients with SLE or Sjogren's despite overall good disease control?

1 Answer available

Would you consider anifrolumab in the management of hematologic manifestations in SLE?

2 Answers available

Would you target the same hydroxychloroquine blood level for discoid lupus compared to systemic lupus?

1 Answer available

Do you escalate treatment for reactive lymphadenopathy in an otherwise stable and asymptomatic patient with lupus?

(assuming that the malignancy evaluation has been completed and the lymphadenopathy is confirmed to be reactive)

1 Answer available

How do you use hydroxychloroquine in patients with lupus nephritis on hemodialysis or peritoneal dialysis?

2 Answers available

Would you have any hesitation to use belimumab in a patient with IgA deficiency?

1 Answer available

Do you have any hesitations for combining belimumab with any of the DMARDs in patients with SLE/RA overlap?

2 Answers available

How do you differentiate a lupus flare versus drug-induced lupus in patients with SLE on a drug associated with DILE?

2 Answers available

Do you find IgA isotypes of anti-beta2-glycoprotein antibodies and anticardiolipin antibodies to be clinically useful in the evaluation for APS?

Do you routinely check IgA anticardiolipin and beta-2 glycoprotein antibody IgA in your practice? And how would a positive result change your manageme...

2 Answers available

How do you treat lupus-associated small fiber neuropathy?

1 Answer available

What do you view as reasonable alternatives to cyclophosphamide in the treatment of neuropsychiatric lupus?

4 Answers available

Do you ever consider treatment outside of the peripartum period in a patient with a history of obstetric APS?

i.e. obstretric APS without thrombosis or SLE

2 Answers available

How do you approach the management of immunosuppression in patients with lupus nephritis that go on to dialysis?

3 Answers available

What is your approach to treating severe manifestations of neuropsychiatric SLE in the setting of concomitant infection?

1 Answer available

Is there a role for immunosuppression in patients with triple positive antiphospholipid antibodies who do not meet the clinical criteria for APS?

2 Answers available

What particular pre-operative considerations should we consider for SLE patients undergoing elective surgery?

1 Answer available

How do you approach DMARD therapy in a patient with lupus and recurrent pericarditis?

1 Answer available

How do you approach the use of commercial testing such as AVISE CTD in clinical practice?

1 Answer available

How do you approach immunosuppressive therapy in lupus-associated pulmonary arterial hypertension?

2 Answers available

Would you use voclosporin or belimumab as adjunctive therapy for treatment of lupus nephritis?

Especially given the recent FDA approval of voclosporin, how should we think about the use of this medication for LN?

3 Answers available

How do you clinically distinguish between cutaneous lupus with photosensitivity and polymorphic light eruption-like reactions?

1 Answer available

Is it ever reasonable to switch to a different TNFi as opposed to switching to an agent in a different class in a case of TNFi induced lupus or psoriasis?

In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect?

1 Answer available

What is your approach to differentiating SLE flare in pregnancy vs pre-eclampsia?

1 Answer available

What is your approach to monitoring lipids in patients with rheumatic diseases such as RA and SLE and do you have a lower threshold to start lipid lowering agents compared to the general population?

2 Answers available

Does the presence of ANCA antibodies in patients with newly diagnosed lupus nephritis alter your approach to management?

1 Answer available

How would you approach localized lymphadenopathy in a patient with lupus whose symptoms are otherwise well-controlled?

2 Answers available

How do you approach monitoring of patients found to have a positive anti-dsDNA antibody without other clinical evidence of SLE?

1 Answer available

How would you advise patients with known stable autoimmune thrombocytopenia regarding the Ad26.COV2.S (Johnson & Johnson/Janssen) vaccine?

1 Answer available

How do you approach the use of low-dose aspirin for primary prevention in non-pregnant patients with SLE and positive aPL antibodies, without clinical criteria for APS?

Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?

1 Answer available

How useful are anti-ribosomal P antibodies in the evaluation for SLE psychosis?

1 Answer available

When is it necessary to monitor the QTc interval in patients on hydroxychloroquine?

2 Answers available

Is it okay to use medications associated with drug-induced lupus in patients with SLE?

1 Answer available

Is there a role for G-CSF treatment for SLE patients with persistent neutropenia?

1 Answer available

What is your approach to treatment of lupus peritonitis?

1 Answer available

Is there a role for measuring hydroxychloroquine blood levels in clinical practice?

If so, are there specific patient populations for which you would use this metric?

1 Answer available

What is your threshold for pursuing bone marrow biopsy in a lupus patient with cytopenias?

2 Answers available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

What is your approach to treating refractory thrombocytopenia in lupus?

2 Answers available

Which immunosuppressed patients with SLE would benefit from antibiotic prophylaxis to prevent pneumocystis pneumonia?

1 Answer available

Is it ever appropriate to use hydroxychloroquine temporarily in higher doses (more than 5mg/kg) to control lupus activity such as skin manifestations?

1 Answer available

How do you interpret a high positive RNP in the setting of a negative ANA and negative sm/RNP?

To my understanding, sm/RNP should also be positive in this situation (and one would assume a positive ANA as well)

1 Answer available

How would you attempt to determine the etiology of intracranial hemorrhage in a patient with newly diagnosed lupus and an active viral infection?

1 Answer available

What is your first choice contraceptive agent for women with SLE?

How do you counsel these patients about hormonal agents?

1 Answer available

Is it okay to use belimumab to treat SLE in a patient who has a history of lymphoma and is on a Bruton's tyrosine kinase inhibitor (such as ibrutinib)?

1 Answer available

Do you think there is a role for belimumab in treating lupus nephritis and if so, in which patients would you considering adding it on?

Did the recently published BLISS-LN trial change your practice?

2 Answers available

Does serologic activity (e.g., high titer dsDNA, low complements) without clinical disease activity in a pregnant lupus patient affect maternal or fetal outcomes?

2 Answers available

Do you continue hydroxychloroquine in lupus patients who develop cardiomyopathy?

1 Answer available

Should gonadotropin-releasing hormone (GnRH) agonists be offered to all women of reproductive age about to undergo treatment with cyclophosphamide?

2 Answers available

What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?

1 Answer available

How do steroids and/or DMARDs affect biopsy results if a renal biopsy for suspected lupus nephritis is delayed?

1 Answer available

Are there any clinical situations in which checking for anti-chromatin antibodies is helpful?

1 Answer available

Do you choose rituximab or calcineurin inhibitors for patients with class IV/V lupus nephritis who are refractory to standard of care therapies?

1 Answer available

How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?

1 Answer available

Is there a minimum work-up necessary in patients with an ANA greater than 1:160 and no clinical symptoms suggestive of lupus (i.e., specific antibodies, UA)?

2 Answers available

Do you use hydroxychloroquine for prevention of neonatal lupus in patients with a positive SSA who are planning on becoming pregnant?

1 Answer available

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

1 Answer available

Papers discussed in this category

Arthritis and rheumatism, 2012-04

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Ann Rheum Dis, 2013 Jun 05

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Arthritis and rheumatism, 2005-09

Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.

Arthritis & rheumatology (Hoboken, N.J.), 2015-05

Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus.

Lupus,

Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.

Best Pract Res Clin Obstet Gynaecol, 2019 Nov 13

Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus.

J. Am. Coll. Cardiol.,

Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.

Arthritis and rheumatism, 1982-11

The 1982 revised criteria for the classification of systemic lupus erythematosus.

Arthritis and rheumatism, 2012-08

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

, 2019 Aug 06

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Arthritis Rheum.,

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Arthritis and rheumatism, 2010-01

Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.

J. Rheumatol., 2019 Sep 01

Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study.

N Engl J Med,

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Southern medical journal, 2016-11

Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus.

Annals of the rheumatic diseases, 2011-05

Lupus Atherosclerosis Prevention Study (LAPS).

Atherosclerosis, 2015 Aug 28

Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.

JAMA ophthalmology, 2014-12

The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.

Can J Ophthalmol,

Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.

J Am Acad Dermatol, 2016 Feb 03

The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2008-10

Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.

Clin Rheumatol, 2006 Dec 21

Blood, 2015 May 13

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).

Blood, 2009 Nov 06

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura.

Annals of the rheumatic diseases, 2011-10

Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

Arthritis Rheum,

Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis.

Rheumatol Int, 2019 Apr 30

Indications for bone marrow examinations in rheumatology.

Clin Exp Rheumatol, 2012 Sep 25

Indications for bone marrow examination in autoimmune disorders with concurrent haematologic alterations.

Wien Klin Wochenschr,

[Rationale for bone marrow examination in patients with inflammatory rheumatic diseases].

Kidney international, 2019-01

A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.

J Rheumatol, 2006 Jul 01

Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares.

Semin Arthritis Rheum,

Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor.

Lupus, 2008-08

Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report.

Arthritis Rheumatol, 2021 Aug 12

Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study.

Int J Clin Pract, 2021 Mar 24

Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.

Mod Rheumatol, 2021 Feb 09

QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.

Heart Rhythm, 2020 Jun 28

Effects of hydroxychloroquine treatment on QT interval.

Blood,

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.

Arthritis care & research, 2018-03

Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.

J Clin Rheumatol, 2020 Sep 18

Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.

Cureus, 2020 Aug 02

A Study on the Relevance of Glucose-6-Phosphate Dehydrogenase Level Screening in Patients with Rheumatic Diseases Prior to Initiating Treatment With Hydroxychloroquine.

The New England journal of medicine, 2003-10-16

Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Lupus, 2007

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.

J Allergy Clin Immunol, 2020 May 22

Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.

Nat Rev Rheumatol,

Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis.

Kidney international, 2009-12

A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis.

Clinical journal of the American Society of Nephrology : CJASN, 2010-07

Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study.

Journal of the American Society of Nephrology : JASN, 2010-08

Comparison of different measures of urinary protein excretion for prediction of renal events.

Am J Kidney Dis, 2016 Sep 16

Timed Urine Collections for Albumin and Protein: "The King Is Dead, Long Live the King!".

J Rheumatol, 2004 Aug

Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis.

Arthritis & rheumatology (Hoboken, N.J.), 2015-07

Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Arthritis Rheum,

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

Lancet, 2021 May 07

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Autoimmunity reviews, 2009-02

The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus.

Arthritis and rheumatism, 2013-07

Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.

Arthritis Rheumatol, 2021 Mar 24

Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.

Rev Med Interne, 2016 Oct 13

[Blood concentration of hydroxychloroquine in systemic lupus erythematosus care: Usefulness and limits].

Arthritis Care Res (Hoboken), 2021 Mar 30

Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

JAMA Dermatol,

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Mod Rheumatol, 2020 Sep 17

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.

Ann Rheum Dis, 2014 Feb 13

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Ann Rheum Dis, 2019 Jan 04

Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.

Ann Rheum Dis, 2014 Apr 16

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

N Engl J Med, 2019 Dec 18

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.

Seminars in arthritis and rheumatism, 2010-12

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Clin Exp Rheumatol, 2012 Oct 17

Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?

Inflamm Bowel Dis,

Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.

Am J Clin Dermatol,

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Journal of the American Society of Nephrology : JASN, 1993-07

Reversible renal failure in the primary antiphospholipid syndrome--a report of two cases.

Arthritis and rheumatism, 2013-02

A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2014-02

Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.

Lupus, 2018-03

Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.

Annals of the rheumatic diseases, 2019-10

EULAR recommendations for the management of antiphospholipid syndrome in adults.

Lupus,

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

Arthritis Rheum,

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

Rheumatology (Oxford), 2021 May 18

Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review.

Am J Transplant, 2013 Jun 13

Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.

Best practice & research. Clinical anaesthesiology, 2014-06

Perioperative analgesia and the effects of dietary supplements.

The Journal of rheumatology, 2016-08

Patients with Systemic Lupus Erythematosus Have Increased Risk of Short-term Adverse Events after Total Hip Arthroplasty.

JCI Insight, 2021 Feb 08

Antineutrophil properties of natural gingerols in models of lupus.

Arthritis Rheumatol, 2021 Jun 01

Sjögren's Disease, Not Syndrome.

Adv Ther, 2018 Mar 20

Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.

J Arthroplasty, 2017 Jun 19

Total Hip Arthroplasty Outcomes: An 18-Year Experience in a Single Center: Is Systemic Lupus Erythematosus a Potential Risk Factor for Adverse Outcomes?

Int J Mol Sci, 2020 Mar 04

Curcumin Attenuates Both Acute and Chronic Immune Nephritis.

Open Access Rheumatol, 2019 Jan 29

Sjögren's syndrome and systemic lupus erythematosus: links and risks.

Respirology, 2016 Dec 17

Anaesthetic management of sleep-disordered breathing in adults.

Lupus, 2013-07

Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity.

Arthritis care & research, 2019-07

Area-Level Predictors of Medication Nonadherence Among US Medicaid Beneficiaries With Lupus: A Multilevel Study.

Arthritis care & research, 2019-11

Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.

J Rheumatol,

Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone.

Lupus Sci Med, 2018 May 14

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort.

Lupus Sci Med,

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.

Lupus, 2015 Jul 10

Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases.

Lupus science & medicine, 2014

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.

The Journal of rheumatology, 2015-11

Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.

Ophthalmology, 2016-06

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

Lupus science & medicine, 2017

Cell-bound complement activation products in SLE.

Journal of immunology research, 2017

Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus.

Lupus science & medicine, 2018

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Clin Pharmacol Ther, 2018 Jun

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.

Lupus Sci Med, 2016

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

Lupus Sci Med, 2016 Feb 01

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

Lupus Sci Med,

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.

ACR Open Rheumatol, 2020 Oct 12

Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).

Arthritis Rheumatol, 2021 May 02

Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.

Ann Rheum Dis, 2012 Nov 10

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).

Arthritis Rheum,

Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.

Lupus,

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.

Arthritis Rheumatol, 2020 Jan 07

Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.

Annals of the rheumatic diseases, 2012-08

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

J Rheumatol, 2013 Nov 15

Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement.

Arthritis Res Ther, 2005 Mar 01

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.

JAMA Ophthalmol, 2015 Oct

Association of systemic lupus erythematosus with uveitis.

JAMA, 2022 Oct 11

Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares.

Front Immunol, 2021 May 14

A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis.

Lupus Sci Med, 2019

Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery.

Current rheumatology reports, 2018-09-10

Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Nat Rev Cardiol, 2019 Jun 26

Role of aspirin in primary prevention of cardiovascular disease.

Seizure, 2020 Apr 26

Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study.

The American journal of medicine, 1996-07

End-stage renal disease and systemic lupus erythematosus.

BMC Nephrol, 2020 Oct 28

Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.

Arthritis Rheum,

Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

Thromb Haemost, 2020 Jul 21

Is There an Additional Value in Detecting Anticardiolipin and Anti-β2 glycoprotein I IgA Antibodies in the Antiphospholipid Syndrome?

Best practice & research. Clinical rheumatology, 2013-06

Cutaneous lupus erythematosus: diagnosis and treatment.

Dermatol Ther, 2016 Apr 12

Review of treatment for discoid lupus erythematosus.

The Journal of rheumatology, 1992-02

Antibiotic allergy in systemic lupus erythematosus: a case-control study.

The British journal of dermatology, 2011-03

A systematic review of drug-induced subacute cutaneous lupus erythematosus.

Current opinion in rheumatology, 2018-09

Drug-induced lupus erythematosus: an update on drugs and mechanisms.

Lupus, 2014 Feb 20

Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced.

Ann Rheum Dis, 2019 Feb 04

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.

Br J Dermatol, 2011 Jul 11

Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart.

Mod Rheumatol, 2016 Feb 17

Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: A retrospective cohort study.

BMJ open, 2019-03-20

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

J Inflamm Res, 2020 Sep 14

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data.

Arthritis Rheumatol, 2017 Apr 07

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

The Journal of rheumatology, 2013-05

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.

Lupus, 2013-02

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Archives of internal medicine, 2004

Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting.

Lupus, 2021 Jan 05

Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort.

Arthritis Rheumatol, 2018 Jun 27

Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015.

Curr Cardiol Rep, 2021 Jul 28

Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.

Clin Exp Rheumatol, 2013 Aug 02

New insights in the pathogenesis and therapy of idiopathic recurrent pericarditis in children.

Arch Dermatol,

Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.

Lupus, 2017 Sep 01

Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.

Lupus, 2016 May 27

Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

Br J Dermatol, 2019 Apr 07

Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus.

Lupus, 2020 Apr 21

Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now?

Autoimmun Rev, 2012 Nov 30

Immunogenicity and autoimmunity during anti-TNF therapy.

Ann Rheum Dis, 2022 Mar 25

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.

Lupus science & medicine, 2018

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.

Arthritis Rheum,

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

Ther Adv Musculoskelet Dis, 2022 Feb 14

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Sleep Breath, 2021 Nov 12

The frequency of obstructive sleep apnea in patients with primary Sjogren's syndrome.

Rheumatol Int, 2019 Jan 02

Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren's syndrome: a randomized-controlled trial.

Lupus,

Sleep disorders and systemic lupus erythematosus.

Clin Immunol, 2020 Oct 02

Airways therapy of obstructive sleep apnea dramatically improves aberrant levels of soluble cytokines involved in autoimmune disease.

Ann Intern Med,

Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis.

Sleep,

Sex differences in obstructive sleep apnea phenotypes, the multi-ethnic study of atherosclerosis.

Worldviews Evid Based Nurs, 2017 Apr 22

The Effectiveness of Exercise in Adults With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis to Guide Evidence-Based Practice.

Am J Clin Dermatol,

Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment.

Lupus, 2020 Feb 09

Systemic lupus erythematosus and diffuse alveolar hemorrhage, etiology and novel treatment strategies.

Am J Med,

Systemic lupus erythematosus and myelofibrosis.

Front Immunol, 2021 Jul 14

Complement C4, Infections, and Autoimmune Diseases.

J Rheumatol, 2017 May 15

Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.

Ophthalmology, 2014-10

Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial.

Br J Ophthalmol, 2015 Apr 22

Ocular manifestations in systemic lupus erythematosus.

Am J Ophthalmol,

Episcleritis and scleritis: clinical features and treatment results.

Transplant Proc,

A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.

The American journal of medicine, 1983-09

Prognostic factors in lupus nephritis. Contribution of renal histologic data.

Arthritis care & research, 2011-06

Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.

Kidney international, 2018-04

Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.

Kidney Int, 2010 Feb 24

Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system.

Journal of the American Academy of Dermatology, 2011-05

Quality of life in cutaneous lupus erythematosus.

Clin Exp Rheumatol, 2013 Aug 02

Pain and pruritus in cutaneous lupus: their association with dermatologic quality of life and disease activity.

J Rheumatol, 2022 Aug 01

Timing and Predictors of Incident Cardiovascular Disease in Systemic Lupus Erythematosus: Risk Occurs Early and Highlights Racial Disparities.

Journal of clinical pharmacology, 2011-08

Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients.

Transpl Int, 2014 Aug 22

Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?

J Clin Med, 2021 Feb 09

Management of Lupus Nephritis.

Lancet Oncol, 2019 Jan

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.

Arthritis Care Res (Hoboken), 2022 Aug 04

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.

The New England journal of medicine, 2019-01-24

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

N Engl J Med, 2022 Dec 22

Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura.

Arthritis and rheumatism, 2009-09-15

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Lupus, 2020 Apr 11

Seroconversion to antinuclear antibody negativity and its association with disease flare in patients with systemic lupus erythematosus.

J Rheumatol, 2009 Oct 15

Ethnic differences in pediatric systemic lupus erythematosus.

ACR Open Rheumatol, 2022 Nov

Association of Race and Ethnicity With Medication Use for Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry.

J Rheumatol, 2009 Jan 22

Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations.

PLoS One, 2022 Oct 10

Diagnostic test accuracy of novel biomarkers for lupus nephritis-An overview of systematic reviews.

Front Immunol, 2022 May 26

Urine ALCAM, PF4 and VCAM-1 Surpass Conventional Metrics in Identifying Nephritis Disease Activity in Childhood-Onset Systemic Lupus Erythematosus.

Rheum Dis Clin North Am, 2022 Feb

Disparities in Pediatric Rheumatic Diseases.

Lupus Sci Med, 2021 Jan

Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study.

Arthritis Care Res (Hoboken), 2020 Aug 19

Cancer risk in a large inception SLE cohort: Effects of demographics, smoking, and medications.

Ann Rheum Dis, 2021 Dec 15

Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.

Lupus Sci Med, 2021 Apr

Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre.

Arthritis Res Ther, 2006

Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus.

Adv Biomed Res, 2016 Aug 30

The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition.

Lupus, 2022 Mar 25

Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.

Rheumatology (Oxford, England), 2018-09-01

The SLE-key test serological signature: new insights into the course of lupus.

J Manag Care Spec Pharm, 2022 Jul 01

Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.

Diagnostics (Basel), 2021 Sep 01

Anti-DFS70 Antibodies for Differentiating Systemic Autoimmune Rheumatic Disease in Patients with Positive ANA Tests: A Systematic Review and Meta-Analysis.

Front Immunol, 2021 May 27

Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond.

Immunol Invest, 1985 Jun

Specificity of the Crithidia luciliae method for detecting anti-DNA antibodies. Effect of absorption for lipoproteins.

Rheumatology (Oxford), 2022 Nov 02

British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.

Semin Arthritis Rheum, 2007 Feb

Common variable immunodeficiency in systemic lupus erythematosus.

J Clin Rheumatol, 2021 Dec 01

Intravenous Immunoglobulin for Inflammatory Myositis: Experience in a Tertiary Medical Center.

Am J Med, 1984 Mar 30

Immunoglobulin G (IgG) subclasses and human disease.

Lupus, 2007

Selective IgA deficiency in children and adults with systemic lupus erythematosus.

Autoimmun Rev, 2022 Aug 24

Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature.

Rheumatology (Oxford, England), 2002-08

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.

Int Arch Allergy Immunol, 2010 Apr 22

Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole.

N Engl J Med, 2003 Oct 23

Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics.

Ann Dermatol Venereol, 1997

[Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases].

Presse Med, 2006 Jul-Aug

[Treatment of chronic lupus erythematosus with sulfasalazine in 18 patients: reappraisal].

Arthritis Rheum, 2004 Oct

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Seminars in hematology, 2002-04

Chronic neutropenia associated with autoimmune disease.

Blood, 2002 Jan 01

Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B.

J Rheumatol, 2020 Apr 01

Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.

J Rheumatol, 2022 Oct 15

Isolated Neutropenia in Systemic Lupus Erythematosus.

Ann Intern Med, 2020 Sep 22

Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.

BMC Rheumatol, 2021 Oct 01

Retinopathy in newly-diagnosed systemic lupus erythematosus: should we screen for ocular involvement?

Clin Ophthalmol, 2011 Oct 04

Isolated cotton-wool spots of unknown etiology: management and sequential spectral domain optical coherence tomography documentation.

Lupus, 2019 Jul 10

Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort.

Ann Med, 2021 Dec

Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.

Arthritis Care Res (Hoboken), 2021 Jul 07

Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.

Front Immunol, 2019 Mar 06

Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome.

Cell Physiol Biochem, 2017 Nov 14

Chloroquine Autophagic Inhibition Rebalances Th17/Treg-Mediated Immunity and Ameliorates Systemic Lupus Erythematosus.

Clin Cancer Res, 2014 Jun 15

Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.

Journal of immunology (Baltimore, Md. : 1950), 2004-08-15

Complete complement components C4A and C4B deficiencies in human kidney diseases and systemic lupus erythematosus.

Arthritis care & research, 2019-01

Obesity is Independently Associated With Worse Patient-Reported Outcomes in Women with Systemic Lupus Erythematosus.

Lupus, 2018-08

Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus.

Arthritis Rheumatol, 2014 Sep

Establishment of gene copy number-specific normal ranges for serum C4 and its utility for interpretation in patients with chronically low serum C4 concentrations.

Arthritis Care Res (Hoboken), 2012 Apr

Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.

Lupus, 2022 Jan 23

The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus.

Arthritis Care Res (Hoboken), 2022 Dec 20

Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort.

Arthritis Rheumatol, 2020 Apr 01

Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.

Ann Rheum Dis, 2022 Jul 07

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.

Ann Rheum Dis, 2022 Oct 05

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.

Ann Rheum Dis, 2023 Jan 05

Transplacental passage of belimumab during pregnancy and follow-up of a child exposed in utero.

Lupus, 2022 Nov 30

Dilemma of belimumab therapy (dis)continuation during pregnancy: Results of a retrospective study in eudravigilance.

Arthritis and rheumatism, 2009-11

Distinct subtypes of myelitis in systemic lupus erythematosus.

Rheumatology (Oxford), 2014 Oct 21

Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus.

Cureus, 2019 Aug 19

Aseptic Meningitis and Depression: The Neuropsychiatric Manifestations of a Patient with Systemic Lupus Erythematosus.

J Rheumatol, 2007 Sep 15

Diagnostic reliability of cerebral spinal fluid tests for acute confusional state (delirium) in patients with systemic lupus erythematosus: interleukin 6 (IL-6), IL-8, interferon-alpha, IgG index, and Q-albumin.

Rheumatol Int, 2007 Jul 20

Acute psychosis in systemic lupus erythematosus.

Lupus, 2017 Feb 26

Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre.

Seminars in arthritis and rheumatism, 2016 Sep 21

The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort.

Clinical rheumatology, 2018 May 11

Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis.

Nature communications, 2021 Jun 07

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Lancet (London, England), 2023 Feb 24

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).

Lancet (London, England), 2023 Feb 24

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).

Clinical and experimental dermatology, 2021 Mar 09

Brodalumab-induced subacute cutaneous lupus erythematosus.

JAAD case reports, 2019 Mar 01

Ustekinumab-induced subacute cutaneous lupus.

Dermatologic therapy, 2020 May 03

Secukinumab-induced subacute cutaneous lupus erythematosus.

Systemic lupus erythematosus

Questions discussed in this category

Papers discussed in this category

Related Topics